Nihon Kohden Cuts FY2025 Forecast as Domestic Weakness and Costs Hit Profit

Nihon Kohden Corporation ( (JP:6849) ) has provided an update.

Nihon Kohden reported consolidated results for the first nine months of FY2025 showing overall sales growth of 3.5% year on year, driven by double-digit overseas sales increases in North America, Europe, and Asia, while domestic sales fell 0.9% amid weaker capital spending by public hospitals and lower AED shipments due to distributor inventory adjustments. Operating income declined 16.5% as lower domestic revenue and higher SG&A from wage hikes and R&D weighed on profitability, and the company also booked ¥2.4 billion in extraordinary losses tied to early retirement payments, prompting a downward revision of full-year forecasts: sales were cut by ¥5 billion to ¥235 billion and operating income by ¥4 billion to ¥20 billion, with management now prioritizing higher-margin in-house products, consumables and services, and hospital IT system installations in the fourth quarter to protect a gross margin target of at least 52% and stabilize earnings.

The most recent analyst rating on (JP:6849) stock is a Buy with a Yen2015.00 price target. To see the full list of analyst forecasts on Nihon Kohden Corporation stock, see the JP:6849 Stock Forecast page.

More about Nihon Kohden Corporation

Nihon Kohden Corporation is a Japanese medical device manufacturer that focuses on patient monitoring systems, defibrillators including automated external defibrillators (AEDs), and related hospital IT and consumables. The company serves both domestic medical institutions and overseas markets, with a growing presence in North America, Europe, and Asia and an emphasis on medium- to long-term enhancement of corporate value.

Average Trading Volume: 618,093

Technical Sentiment Signal: Buy

Current Market Cap: Yen285.9B

For detailed information about 6849 stock, go to TipRanks’ Stock Analysis page.